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  The bHLH transcription factor Hand1 (Heart and neural crest-derived transcript-1) has a 
fundamental role in cardiovascular development; however, the molecular mechanisms have 
not been elucidated. In this paper we identify Thymosin   β 4  ( T  β 4 / Tmsb4x  ), which encodes 
an actin monomer-binding protein implicated in cell migration and angiogenesis, as a direct 
target of Hand1. We demonstrate that Hand1 binds an upstream regulatory region proximal 
to the promoter of T  β  4 at consensus Thing1 and E-Box sites and identify both activation and 
repression of T  β  4 by Hand1, through direct binding within either non-canonical or canonical 
E-boxes, providing new insight into gene regulation by bHLH transcription factors. Hand1-
mediated activation of T  β  4 is essential for yolk sac vasculogenesis and embryonic survival, and 
administration of synthetic TB4 partially rescues yolk sac capillary plexus formation in Hand1-null 
embryos. Thus, we identify an   in vivo   downstream target of Hand1 and reveal impaired yolk sac 
vasculogenesis as a primary cause of early embryonic lethality following loss of this critical 
bHLH  factor.          
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and1 (Heart and neural crest-derived transcript-1) is a class 
B bHLH factor, critical for the development of three embryo-
logically distinct lineages: trophoblast of the placenta, 
extraembryonic mesoderm derivatives and cardiomyocytes of the 
left   ventricle and outfl  ow tract myocardium.   Hand1 -null  embryos 
arrest in development at around embryonic day 8.0 (E8.0) because 
of extraembryonic defects  1 – 3 . Trophoblast giant cells, responsible for 
establishing the implantation chamber by invasion into the mater-
nal decidua, fail to diff  erentiate from trophoblast precursors of the 
ecto-placental cone  1 , and the visceral yolk sac lacks defi  ned vascula-
ture and shows extensive haemorrhaging  1,3  . Tetraploid aggregation 
experiments rescued extraembryonic defects, enabling develop-
ment to E10.5, when chimeric embryos died presenting with cardiac 
anomalies such as abnormal looping and impaired specifi  cation of 
the ventricular myocardium  1 . However, given the potential contribu-
tion from both placental and  /  or yolk sac defects, the primary cause 
of lethality of  Hand1  mutant embryos has not been determined and, 
moreover, despite previous identifi  cation of diff  erential expression 
of vascular genes downstream of Hand1  4  , there is no insight into 
how Hand1 might function in these lineages at the level of direct 
downstream targets. 
  To gain mechanistic insight into Hand1 function during deve-
lopment, we screened for potential target genes of Hand1 using 
representational diff  erence analysis between pools of mRNA from 
  in vitro- diff  erentiated wild-type and   Hand1  -null embryoid bodies 
(EBs)  5  . A number of genes implicated in cell motility and guidance 
were identifi  ed as being diff  erentially expressed in the absence of 
  Hand1  . One such gene, the actin monomer-binding protein, thy-
mosin   β 4  ( T  β 4 / Tmsb4x  ), was downregulated in the   Hand1 -null 
background, and both temporally and spatially coexpressed with 
  Hand1 in vivo  , notably in the left   ventricle and outfl  ow tract of the 
developing heart at mid-gestation and appropriately mis-expressed 
in  Hand1 -null embryos. TB4 ,  the predominant mammalian isoform 
of the   β  -thymosin family, sequesters monomeric actin (G-actin), 
which is then de-sequestered by profi  lin to induce rapid fi  lament 
(F-actin) polymerization. Th  is process underlies the formation of 
fi  lamentous structures such as lamellipodia to mediate cell move-
ment. Specifi  cally, TB4 has been shown to promote the migration of 
endothelial and other vasculogenic precursor cells and as such is an 
important regulator of the closely related processes of vasculogenesis 
and angiogenesis  6 – 10 . 
  Here, we validate   T  β 4    as a legitimate downstream target of 
Hand1 and investigate the functional role of the Hand1  –  T  β 4  path-
way during embryogenesis. Reporter gene co-transfection experi-
ments, electrophoretic mobility shift   assays (EMSAs) and chromatin 
immunoprecipitation (ChIP) confi  rm that Hand1 directly binds to 
upstream sequences proximal to the   T  β 4    promoter to confer com-
plex transcriptional regulation, seemingly activating and repressing 
transcription at diff  erent consensus binding sites. We reveal how 
ectopic administration of TB4 rescues vascular diff  erentiation in 
  Hand1  -null embryonic stem cells and defective yolk sac vasculo-
genesis in   Hand1  -null embryos to prolong survival. Th  us, we are 
able to defi  ne an early essential role for Hand1 in regulating yolk sac 
vessel development with   T  β 4    as a downstream mediator of Hand1 
vascular function.   
 Results  
     T  b 4    is bound by Hand1 at conserved E-box and Th  ing1  sites   .     To  
validate   T  β 4    as a legitimate downstream Hand1 target, we performed 
a range of transcriptional reporter and DNA-binding assays. Th  e 
functional   T  β 4    promoter has previously been identifi  ed as residing 
between residues     −    278 and     +    410, relative to the ATG 11 . We identifi  ed 
two upstream putative Hand1-binding sites, a canonical E-Box 
site,  CACATG  (consensus  CANNTG;  nucleotide  positions      −    1913 
to         −        1908) for the binding of bHLH  /  E-factor heterodimers and a 
degenerate  E-Box,  TCTCTG  (nucleotide  positions      −    1691  to      −    1686), 
which matches the preferred binding site of HAND1  /  E-factor 
heterodimers (consensus NCTCTG  12 ;   Fig.  1a ).  Th  ese binding 
sites are conserved throughout mammals, such as human, 
rhesus and dog, but not throughout chicken or lower vertebrates 
species such as frog and zebrafi  sh, consistent with the evolution 
of the chorioallantoic and yolk sac placenta (  Fig. 1b  ;   http://www.
ecrbrowser.dcode.org/ ).  An  870-bp  fragment  (    −    2002  to      −    1132) 
containing E-boxes was placed upstream of a luciferase reporter and 
minimal promoter and we established point mutation constructs 
in which single residues within half-sites, previously identifi  ed as 
critical for Hand1 or E-Factor binding (Th  ing1 mutants 1 and 2; 
E-Box mutant 1) or as an alternate core residue for E-Factor binding to 
determine specifi  city (E-box mutant 2)  12  , were individually mutated 
(  Fig. 1c  ). Accordingly, NIH-3T3 cells, co-transfected with the   T  β 4    
luciferase construct and full-length   Hand1   cDNA, were assayed for 
luciferase activity. Hand1 was shown to induce a 10-fold activation 
of   T  β 4    expression (  Fig. 1d  ,   P     <    0.001).  Activation  was  completely 
abolished by point mutation of the Th  ing1 box, selectively at the 
half-site of Hand1 binding (  P     <    0.01;   Fig.  1d ),  suggesting  that   T  β 4   
is a direct target of Hand1, with activation occurring, primarily, at 
the Th   ing 1 box. In contrast, point mutations in the E-box resulted 
in increased transcriptional activity (2.6-fold increase for the E-box 
mutant 1, relative to wild type), indicative of an additional level of 
transcriptional control, whereby Hand1  /  E-factor binding at this site 
can repress transcription (  Fig. 1d  ). Mutation of the Hand1-binding 
half-site within the canonical E-box to an alternate core E-box 
residue resulted in the greatest increase in transcriptional activity 
(  Fig. 1d  ), indicating a high degree of specifi  city for Hand1 binding 
of the specifi  c E-Box within the   T  β 4    upstream region. To examine 
the ability of Hand1 to bind to the   T  β 4    regulatory sequence, EMSAs 
were performed using 26-bp double-stranded oligonucleotides 
corresponding to the E-box and Th   ing1 sites, along with 10 fl  anking 
nucleotides on either side.   In vitro-  translated Hand1, as a test for 
homodimer binding, was shown to shift   the migration of both 
binding site oligos (  Fig. 1e  ). Th  e greater intensity of the shift  ed 
E-box oligo implies stronger binding at the E-box compared with 
the Th   ing1 box (  Fig. 1e  ). We then investigated binding of   in vitro-
  translated Hand1 in combination with   in vitro- translated  E-factor 
(E12) at the E-box and revealed a resulting band shift   comparable 
to that for an optimal Th  ing1 box (CGTCTG)  12   positive  control 
(  Fig. 1f  ). Th  is was supported by additional EMSAs with   in vitro -
translated tethered Hand1-E-Factor to further investigate hetero-
dimer binding, which again showed stronger binding at the E-box 
(ITF2  ;   Fig.  1g ).  Signifi  cantly, binding was virtually undetectable 
when oligonucleotides containing half-site point mutations were 
used (  Fig. 1e  ) and excess cold (unlabelled) of either half-site mutant 
was unable to compete away binding relative to that competed by 
cold wild-type oligonucleotide (  Fig. 1f,g  ). 
 Collectively,   in vitro   DNA-binding analyses not only confer 
direct binding at specifi  c sites within the   T  β 4    proximal  5 ′   region 
to Hand1, but for the fi  rst time provide evidence for binding within 
either the preferred Th   ing1 box or the canonical E-Box, which in 
turn results in Hand1-mediated diff  erential  eff  ects  (activation 
through the Th   ing1 box and repression through the E-box) on   T  β 4   
transcription.   
    T  b 4    is a direct   in vivo   target of Hand1   .     D e fi nitive   in vivo   bind-
ing of Hand1 to the   T  β 4    promoter was demonstrated by ChIP from 
both EBs and whole embryos. Chromatin from 14-day diff  erenti-
ated wild-type EBs was immunoprecipitated using a polyclonal 
  α  -Hand1 antibody and the binding of Hand1 to the   T  β 4    regulatory 
sequence was ascertained by PCR using several primer sets across 
this region (  Fig. 2a,b  ). Chromatin from   Hand1  -null EBs was used 
in parallel as a control for antibody specifi  city and all PCR products 
were validated by sequencing. Th   ese experiments not only confi  rm 
that Hand1 can be induced to bind and regulate   T  β 4    transcription ARTICLE   
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  in vitro   but also show that binding occurred   in vivo   with EB dif-
ferentiation. We next sought to extend these studies to verify that 
the same direct interaction occurred in the developing embryo. 
Interestingly, the T  β  4 proximal upstream regions were immuno-
precipitated using the Hand1 antibody from whole E8.5 embryos 
but either failed to be immunoprecipitated, in the case of the region 
containing the Th   ing1 box, or only relatively weakly (15-fold less by 
means of scanning densitometry), in the case of the region contain-
ing the E-box from E11.5 embryos (  Fig. 2b  ), providing additional 
insight into the temporal control of Hand1-mediated regulation of 
  T  β 4   expression. Western analysis on E8.5 wild-type and  Hand1 -null 
embryos confi  rmed the specifi  city of the Hand1 antibody used in 
ChIP experiments ( Fig. 2c ), which was independently further verifi  ed 
by our inability to ChIP from   Hand1 -null  EBs.   
  Th   e  Hand1 – T b  4 pathway regulates vasculogenesis in EBs   .     Tr a n s -
criptional and DNA-binding assays identifi  ed   T  β 4    as a direct target 
of the transcription factor, Hand1. We sought to establish the func-
tional signifi  cance of the Hand1  –  T  β  4 pathway   in vivo ,  by  determin-
ing the role of   T  β 4    in Hand1-dependent developmental processes. 
Given the requirement for T β 4 in coronary vasculogenesis and angio-
genesis, we investigated whether reduced levels of TB4 contribute to 
vascular defects in   Hand1  -null embryos. Initially, we made use of 
  Hand1 -null EBs as a surrogate model for vasculogenesis  13,14 .  Hand1 -
null EBs were morphologically indistinct from wild-type EBs and 
able to undergo diff  erentiation into complex cell types, such as beat-
ing cardiomyocytes, and primitive morphogenesis, including vesicle 
formation and cavitation. We fi  rst investigated the relative expres-
sion of   Hand1   and   T  β 4    over a time course of EB diff  erentiation. As 
wild-type EBs were diff  erentiated in fl  oating culture, expression of 
  Hand1 ,  fi  rst apparent at day 4, became upregulated and reached a 
peak of expression at day 8.   T  β 4    expression was fi  rst detected aft  er 
6 days of diff  erentiation. Signifi  cant upregulation of   T  β 4  ,  followed 
immediately aft  er   Hand1   expression, reached peak level (10 days of 
diff  erentiation). Th   e lag between the onset of   Hand1   expression  and 
upregulation of   T  β 4    likely refl  ects the earlier expression of   Hand1  
in EB cell lineages that do not express   T  β 4    (for example, defi  nitive 
mesoderm). Appropriate succession of   T  β 4    relative to   Hand1   in EB 
diff  erentiation is consistent with the notion that   T  β 4    is a bona fi  de 
  Hand1   target (  Fig. 3a  ). Real-time quantitative reverse transcription 
(qRT)  –  PCR, over the equivalent time course of both wild-type R1 
and   Hand1  -null (6.13) EB diff  erentiation, confi  rmed appropriate 
downregulation of   T  β 4    expression in   Hand1 -null  EBs  ( Fig.  3b – d ), 
although   T  β 4    levels were not completely ablated, suggesting that, 
                 Figure  1     |          Hand1  is  a  transcriptional  regulator  of  T  4. A consensus E-box (CACATG, in red) and Thing1 box (TCTCTG, in blue) are found within a 
regulatory region upstream of the   T  β 4    promoter (  a  ). Sequence alignment reveals that the Hand1-binding sites proximal to the   T  β 4    promoter are conserved 
in mammals. Evolutionarily conserved regions are indicated by coloured peaks and represent at least 100     bp of sequence and 70 %   identity; 
red peaks represent upstream intergenic regions; yellow peaks represent untranslated regions; blue peak is the ﬁ  rst exon of T  β  4 and the salmon region 
is the intronic sequence (  http:/ /www.ecrbrowser.dcode.org/  ; (  b  )). Schematic to illustrate point mutations introduced into the respective half-sites of 
E-box and Thing1 box; numbers refer to the nucleotide location of each point mutation relative to the ATG of T  β 4  ( c  ). An 870-bp fragment containing 
the regulatory sequences was placed upstream of a luciferase reporter to assay for transcriptional activity. Luciferase reporter assays indicate a 10-fold 
activation of a T  β 4  reporter  construct  by  Hand1  ( *  *  *  P     <    0.001,  Student ’ s   t -test)  ( d  ). Electrophoretic mobility shift assays demonstrate binding of Hand1 
to both the E-box and Thing1 boxes within the T  β  4 proximal regulatory sequence, which is abolished by point mutation of E-box residues and severely 
diminished by point mutation of the Thing1 box (  e  ). EMSA binding of Hand1 and E12 to the E-box within the T  β  4 proximal regulatory sequence compared 
with an optimal Thing1 Box  12  (  f  ). Binding of E-box and Thing1 boxes by a tethered Hand1-E-factor (Hand1  –  ITF2) heterodimer is not competed away by 
mutant oligonucleotides (as depicted in (  c  )) containing a point mutation in the half sequence for either E-factor or Hand1 binding (  g  ); IVT controls of 
empty vector alone are shown in the left-hand lanes for each of   e  –  g  . Error bars in   d   are s.e.m. of   n     =    mean  of  three  separate  transfection  experiments, 
with triplicate wells for each treatment per experiment. IVT,   in vitro  -translated; RLU, relative light units.   ARTICLE
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during diff  erentiation of the embryo proper,   Hand1   is not the only 
factor regulating   T  β 4    gene expression. We then examined expres-
sion levels of key vascular genes in   Hand1  -null EBs and observed 
reduced expression of both endothelial (TIE-2; to 4.1  %  ;   Fig. 3e  ) 
and smooth muscle (  α  -smooth muscle actin;   α  -SMA; to 62.7  %  ) 
cell markers (  Fig. 3f  ). To determine the extent to which the loss of 
T  β  4, downstream of Hand1, accounted for the reduced expression 
of these specifi  c vascular markers, EBs were cultured in the presence 
of  100-ng   ml     −     1   synthetic TB4 from day 4 of diff  erentiation until col-
lection at day 14. Addition of TB4 to the culture medium was suf-
fi  cient to restore endothelial diff  erentiation, represented by TIE-2 
levels, the more severely downregulated marker in the   Hand1 -null 
situation  ( Fig.  3e ).   α  -SMA levels, which were modestly diminished 
in the absence of   Hand1  , were signifi  cantly elevated (2.2- to 4.5-
fold) beyond control levels, not only in   Hand1  -null EBs but also 
in   Hand1  -heterozygous and wild-type EBs (  Fig. 3f  ), implying that 
TB4 is a potent regulator of embryonic smooth muscle cell diff  eren-
tiation. However, as smooth muscle protein levels were not greatly 
reduced in the   Hand1  -null background, it is possible that, in this 
context, TB4 functions in smooth muscle diff  erentiation in a parallel 
pathway independent of Hand1.     
  Th   e  Hand1 – T   4 pathway regulates yolk sac vasculogenesis   .     We  
next investigated the implications of these fi  ndings by addressing 
the role of the Hand1  –  T  β  4 pathway in the development of the yolk 
sac vasculature proper. As   Hand1   was shown to be expressed in the 
mesodermal layer of the visceral yolk sac  3,4  , as a contributory fac-
tor to the haemorrhagic yolk sac phenotype reported in   Hand1 -null 
embryos, we fi  rst examined the developing yolk sac vasculature as 
a potential lineage for   Hand1  –  T  β 4    coexpression.   In situ   hybridiza-
tion revealed   T  β 4    expression in the blood islands of the yolk sac 
at E8.5 (  Supplementary Fig. S1a  ) and in developing vessels at E9.5 
and E10.5 (  Supplementary Fig. S1b  –  d  ). Whole-mount immunofl  u-
orescence, on wild-type embryos, revealed T  β 4  coexpression  with 
Hand1 throughout the yolk sac mesoderm at E8.5 (  Fig. 4a,b)   and 
in endothelial cells at E8.5 (not shown) and E9.5 (  Fig. 4c  ). T  β 4  was 
not expressed in smooth muscle cells, as revealed at E9.5 (  Supple-
mentary Fig. S2a – d ). Hand1 follows an equivalent pattern of expres-
sion at E9.5, exclusively localized within the platelet  /  endothelial cell 
adhesion  molecule  (PECAM)    +      endothelium  ( Fig.  4d,e )  and  absent 
from the smooth muscle layer of the developing yolk sac vasculature 
(  Fig. 4f,g  ). Interestingly, Hand1 subcellular localization changes from 
exclusively nuclear at E8.5 to perinuclear at E9.5 (as confi  rmed by 
immunostaining with three independent   α  -Hand1 polyclonal anti-
bodies), with increasing endothelial cell diff  erentiation (  Fig. 4a,b,d 
and e ), and is downregulated on vascular maturation ( Supplementary 
Fig.  S2e – h ).   
  Rescue of   Hand1   vascular defects by synthetic TB4   .     I m p o r t a n t l y,  
TB4 was signifi  cantly downregulated (9.03-fold,  P     ≤    0.01) in  Hand1 -
null yolk sacs to levels equivalent to background (no primary  /
  secondary antibody-alone controls; not shown), as determined by 
immunostaining (  Fig. 5a  –  f  ) and ImageJ analysis for quantifi  cation 
(  Fig. 5g  ). Subsequent immunohistochemistry on   Hand1 -mutant 
embryos indicated a lack of vascular plexus formation in the yolk 
     Figure  2     |          Hand1  binds  to  a  region  proximal  to  the  T   4 promoter   in vivo .  
Regions of the T  β  4 sequence containing either the E-box (F1  –  R1; forward 
(F) and reverse (R) primer sequences are underlined with arrowhead for 
orientation) or the Thing1 box (F2  –  R2 primer sequences as indicated) 
were PCR-ampliﬁ  ed using indicated primers (  a  ). Chromatin containing 
the E-box and the Thing1 box was individually immunoprecipitated from 
wild-type (WT) embryoid bodies but not from   Hand1 -null  embryoid 
bodies as conﬁ  rmation of antibody speciﬁ  city (  b  ). Hand1 binds to the 
T  β  4 promoter in the E8.5 embryo but only weakly at the E-box of the 
promoter at E11.5. A 469-bp product containing both binding sites (F1  –  F3 
primer sequences as indicated) could be ampliﬁ  ed from both EBs and E8.5 
embryos under PCR conditions of reduced stringency. Lanes 1, 2 and 3 refer 
to input, no antibody control and Hand1 antibody, respectively. Speciﬁ  city 
of the antibody used for ChIP was conﬁ  rmed by western blot analysis of 
E8.5  WT  (    +     /     +    )  and   Hand1 -null  (    −     /     −    )  embryos  ( c  ); black arrowhead 
highlights speciﬁ  c Hand1 band; ns, nonspeciﬁ  c.   
       Figure  3     |          Hand1  regulates  vascular  differentiation  in  embryoid  bodies. 
  T  β 4    and Hand1 levels were visualized by northern blotting (  a )  and 
quantiﬁ  ed relative to   Gapdh   levels (  b  ). Real-time qRT  –  PCR was used 
to measure   Hand1   ( c  ) or   T  β 4    expression (  d  ) during a time course of 
differentiation in wild-type (R1) and   Hand1  -null (6.13) EBs. T  β  4 levels are 
signiﬁ  cantly downregulated in a   Hand1  -null background (day 6,   *    P     ≤    0.05; 
days  8 – 16,   *  *  P     ≤    0.01;  Student ’ s   t -test)  ( d  ). Western blot analysis showed 
that vascular markers, both endothelial (  e  ) and smooth muscle (  f ),  are 
diminished in   Hand1  -null embryoid bodies (EBs), as quantiﬁ  ed by scanning 
densitometry, normalized against GAPDH. Expression levels of these 
markers, TIE-2 (  e  ) and   α -SMA  ( f  ), are restored by supplementing the 
culture  medium  with  synthetic  TB4  (    +    T β  4). Error bars in   c   and   d   represent 
s.e.m., where   n         =       mean of three samples per time point. AU, arbitrary units.   ARTICLE   
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sacs of mutant embryos as compared with heterozygous littermates 
at E8.5 (  Fig. 6a,b  ). Such defects in yolk sac vasculogenesis coin-
cided, as previously reported  1  , with an arrest in embryonic develop-
ment. In contrast, wild-type and heterozygous littermate embryos 
had appropriately turned and developed within a yolk sac con-
taining  a  well-organized  capillary  plexus  composed  of  PECAM    +     
endothelial cells arranged in the characteristic honeycomb pattern 
(  Fig. 6a  ). Intraperitoneal injection of pregnant female mice with 
TB4  (6   mg   kg     −     1  ) was performed to determine whether defective 
vasculogenesis in   Hand1  -null yolk sacs could be rescued by TB4. 
  Hand1  -null embryos treated with TB4 were recovered at E8.5 in 
which yolk sacs displayed an appropriately formed capillary net-
work (PECAM immunohistochemistry,   Fig. 6c  –  f  ) and in which the 
embryo had developed beyond the primitive arrested head fold and 
body axis stage of the conventional mutants. Appropriate uptake of 
TB4 in the yolk sac vasculature was confi  rmed by enzyme-linked 
immunosorbent assay (ELISA) on treated yolk sac tissue, which 
revealed a signifi  cant fi  vefold elevation in TB4 levels (  Fig. 6g  ). In 
addition, real-time qRT  –  PCR revealed that reduced   T  β 4    expression 
in   Hand1   mutant yolk sacs was elevated beyond the level observed 
in control   Hand1   heterozygotes aft  er administration of synthetic 
TB4 (  Fig. 6h  ); this not only further confi  rmed appropriate localiza-
tion of TB4 treatment to the developing yolk sac   in utero ,  but  also 
suggested an autoregulatory eff  ect of TB4 on its own gene expres-
sion. In two independent   Hand1  -null lines (conventional targeted 
  Hand1   allele and a tTA knock-in to the   Hand1   locus), the mutant 
phenotype at E8.5 is virtually 100  %   penetrant  1,15 ,  as  confi  rmed in 
all vehicle-treated mutants examined in this study, suggesting that 
TB4-rescued mutants do not simply represent   Hand1   mutants pre-
senting with a less-severe phenotype. Th   erefore, we conclude that 
TB4 is suffi   cient to rescue vasculogenic defects in the embryonic 
yolk sac that arise because of an absence of   Hand1 .  Conventional 
  Hand1   mutants were rarely observed at E9.5 (  n     =    1  from  5  litters / 49 
embryos,  expected  number    =    12.5;  25 % )  and  those  that  could  be 
isolated displayed gross phenotypical defects compared with hetero-
zygous littermates (  Fig. 6i  ), leading to resorption (  Fig. 6j  ); however, 
TB4-rescued   Hand1   mutants were recovered, but had evidently 
arrested in development by this stage (  Fig. 6k  ). At E9.5, TB4-rescued 
  Hand1  -null embryos were recovered with 16  –  18 somite pairs, com-
pared  with  17 – 23  in  wild-type / heterozygous  littermates  (based  on 
  n     =    6 litters), representing a clear progression in development beyond 
the 8  –  12 somite pairs observed at E8.5. Th   e  E9.5   ‘ rescued ’   embryos 
lacked large, blood-fi  lled, vitelline vessels and the accompanying 
highly organized meshwork of secondary smaller vessels apparent 
in wild-type yolk sac at the equivalent stage (  Fig. 6l  –  r  ). Th  is sug-
gests that T  β  4 rescued early yolk sac vasculogenesis at E8.5 but was 
insuffi   cient to rescue angiogenic remodelling of the primary vascular 
plexus at E9.5 to ensure continued embryonic growth and survival. 
  Real-time qRT  –  PCR on E8.5 yolk sacs from   Hand1   hetero-
zygous and homozygous mutants confi   rmed   ‘ rescue ’   of  vascular 
gene expression during yolk sac vessel development aft  er treatment 
with synthetic TB4 (  Fig. 7  ). Elevated levels of   Vegf ,   Flt1   and   Pecam  
expression in   Hand1  -null yolk sacs, consistent with that observed 
previously  4  , were returned to control levels aft  er TB4 treatment 
( Fig. 7a ). Western analysis on lysates from E8.5 yolk sacs for PECAM 
expression confi  rmed the real-time qRT – PCR data. PECAM protein 
      Figure  4     |          TB4  and  Hand1  are  coexpressed  in  the  developing  yolk  sac. TB4 is coexpressed with Hand1 in the yolk sac mesoderm at E8.5 as determined 
by immunostaining with epiﬂ  uoresence (  a  ) and confocal microscopy (  b  ). White arrowheads in   a   (merged, bottom panel) highlight T  β  4 and Hand1 
double-positive cells. TB4 is expressed in endothelial cells of yolk sac capillaries at E9.5 (  c  ), as detected by coexpression with PECAM (  c  ; panel 4). Hand1 
is expressed in yolk sac PECAM       +        endothelial cells and becomes localized to perinuclear regions with differentiation of the endothelium (  d ,   e );  white 
arrowheads  highlight  clusters  of  Hand1    +     / PECAM    +      endothelial  cells  in   d   (merged bottom panel) with a higher magniﬁ  cation view of costained cells 
within the plexus in   e  . Hand1 is not expressed in smooth muscle cells at E9.5, as indicated by mutually exclusive localization of Hand1       +        cells and those 
stained for   α  -smooth muscle actin (  α SMA;   f ,   g  ); white arrowheads highlight   α SMA    +      cells  lining  the  Hand1    +      vascular  endothelium  at  low  ( f  ) and high 
magniﬁ  cation (  g  ). Each top panel label (  a – g  ) refers to the subsequent set of four vertical panels. Scale bars indicate 20       μ m  ( a );  10    μ m  ( b );  and 
50    μ m  ( c  –  g ).  ARTICLE
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was elevated in the   Hand1  -null background, but returned to con-
trol levels as observed in heterozygous littermates aft  er TB4 treat-
ment (  Fig. 7b  ). Th  e expression data suggest that vascular genes 
and proteins, such as PECAM, are mis-regulated in a   Hand1 -null 
background, with compensatory increases occurring in yolk sac 
endothelial cells in the absence of appropriate remodelling and 
plexus formation. 
  Genes encoding members of upstream TGF  β -signalling  path-
ways,  Tgf  β 1   and  Tgf  β rII , with associated expression of either  Smad5  
and   Endoglin   (  Fig. 7c  ), which, at this comparatively early stage, are 
indicative of endothelial cell proliferation and migration, or   Smad2  
(  Fig. 7c  ), which functions in endothelial cell diff  erentiation dur-
ing vasculogenesis (reviewed by Gaengel   et al.  16  ), were also rescued 
to the levels observed in control   Hand1   heterozygous yolk sacs. In 
addition, expression of   Notch1 ,   2   and   4   (  Fig. 7d  ) was also reduced 
to control levels aft  er administration of TB4, suggesting appropriate 
modulation of VEGF-signalling and vascular patterning (reviewed 
by Roca and Adams  17  ). Consistent with the TB4-mediated   ‘  res-
cue  ’   being restricted to vasculogenesis at E8.5, we did not observe 
changes in expression of genes encoding members of the platelet-
derived growth factor (PDGF)-B  –  PDGFR  β   pathway, known to 
have a key role in mural cell recruitment during angiogenesis.  16     
 Discussion 
  During development, the yolk sac gives rise to blood and the earli-
est vessels, and functions as the developmental circulatory system 
to sustain early embryonic life. Th   e initial requirement for complex 
yolk sac vasculature is then superseded by the placenta, which takes 
over the supply of maternally derived nutrients and oxygen to the 
rapidly developing fetus. Th   e bHLH transcription factor Hand1 is 
fundamentally required for development of both the yolk sac and 
trophoblast cells of the placenta and, at later stages, in cardiac loop-
ing morphogenesis and ventricular specifi   cation of the embryo 
proper. However, to date, as both placentation  1   and extraembryonic 
mesoderm / yolk  sac  defects 3,4   contribute towards the phenotype 
of   Hand1  -null embryos, it has not been possible to determine the 
individual contribution of each component or which is primarily 
responsible for the early embryonic lethality. Moreover, the molecu-
lar target genes for Hand1 and downstream eff  ectors, which orches-
trate these essential embryonic events, have not been defi  ned. 
  Here, we identify   Th  ymosin   β 4    as a bona fi  de target of Hand1 
and defi  ne a specifi  c physiological role for the Hand1  –  T  β 4  axis 
in regulating yolk sac vasculogenesis. Yolk sac vessel anomalies in 
  Hand1  -null embryos manifest at an earlier stage (E8.5) than almost 
all other reported yolk sac mutants, in which defective angiogenesis 
and vascular remodelling (PDGF receptors  18 ,  Neuropilin-1 19 ,  Ets-
related factor, TEL  20 ,  LBP-1a 21 ,   α -5 β 1  integrin 13  ) or smooth muscle 
cell recruitment (Erk  –  5 (ref.   22  )) is evident between E9.0  –  10.0. We 
report the fi  rst rescue of extraembryonic vascular defects in any 
context to date, such that administration of synthetic TB4 during 
pregnancy is suffi     cient to restore vasculogenesis to   Hand1 -null 
embryonic yolk sacs. Th   e fact that TB4 treatment enabled the recov-
ery of   Hand1  -null mutants as late as E9.5 implicates impaired yolk 
sac vasculogenesis as a contributing factor to the early lethality in 
  Hand1  -null embryos. However, failure of development beyond E9.5 
in   ‘  rescued  ’   mutants suggests an absolute requirement for   Hand1  
in other critical aspects of embryonic development, such that TB4-
treated embryos likely die because of a combination of abnormal 
trophoblast  /  placenta formation and failed later-stage yolk sac 
remodelling. A recent study targeting   Hand1   specifi  cally in extra-
embryonic mesoderm  23   resulted in lethality at stages equivalent to 
those previously reported for systemic   Hand1   knockouts 3,4  . Loss of 
  Hand1  in extraembryonic mesoderm suggests that the role of Hand1 
in the yolk sac anlage is critical for embryonic viability and may rep-
resent the primary cause of lethality in   Hand1 -null  mutants. 
  Yolk sac defects in   Hand1  -null mutants have previously been 
attributed to impaired remodelling of the vascular plexus and defec-
tive recruitment of smooth muscle cells to the endothelial network  4 . 
Th  ese events occur aft  er vasculogenesis, and are indicative of the 
fact that   Hand1   mutants in this earlier study survived to a more 
advanced stage (E9.5), as compared with our null embryos (E8.5), 
having been generated by distinct targeting to derive an alternate 
mutant allele and maintained on a diff  erent genetic background  4 . 
Precedent for allele-specifi  c targeting generating phenotypes with a 
diff  erent stage of onset and varying severity exists for a number of 
genes, including the cardiac transcription factor Gata4  24,25 ,  whereby 
    Figure  5     |          TB4  is  downregulated  in   Hand1  -null yolk sacs. Hand1 and TB4 
are coexpressed in the developing vasculature of the yolk sac at E8.5 in 
wild-type  (    +     /     +    )  embryos  ( a ,   c  ) but not in   Hand1 -null  yolk  sacs  (    −     /     −    )  ( e ). 
TB4 expression is found in the cytoplasm of wild-type embryos as revealed 
by counterstaining nuclear DNA with   bis -benzamide  ( b ,   d  ), but is not 
detected in   Hand1  -null yolk sacs (  f  ). TB4 is evident in the remodelling 
vascular plexus (  c  ; highlighted by white arrowheads) in wild-type yolk 
sacs but signiﬁ  cantly downregulated in   Hand1  -null yolk sacs (  e  –  g ).  Images 
were captured at equivalent light intensity and ﬁ  lter settings and levels of 
TB4 were detected in   Hand1  -null yolk sacs as equivalent to background as 
determined by ImageJ scans of six regions of yolk sac vasculature across 
two wild-type and two   Hand1  -null yolk sacs (  g  ). Error bars are s.e.m., where 
  n     =    mean  ImageJ  ﬂ  uorescence across six regions of yolk sac vasculature 
per  genotype.   *  *  P     ≤       0.01 (Student  ’  s t-test). Scale bar in   a ,  40    μ m  ( a – f ). 
AU, arbitrary units.   ARTICLE   
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the variation is likely due to genetic modifi  er or off  -target eff  ects. 
Impaired angiogenesis was associated with an upregulation in   Vegf , 
  Ang1   and   Ephrin B2   at E9.5 but without insight into the functional 
downstream pathway(s) or any direct eff  ects on gene expression  4 . 
Consistent with these later-stage fi  ndings, we observed an upregula-
tion in components of the  Vegf ,  Tgf  β    and  Notch  pathways in  Hand1 -
null yolk sacs at E8.5, suggesting that Hand1 may also be required 
for suppression of specifi  c cohorts of vascular genes at earlier stages. 
Importantly, whereas mis-expression of these factors may underlie 
defective angiogenesis and mural cell recruitment at E9.5  4 ,  each  of 
these specifi  c pathways is also critical for endothelial cell migra-
tion, proliferation and diff  erentiation during vasculogenesis  16   and 
their mis-expression can account for the earlier  Hand1 -null yolk sac 
pheno  type we observe at E8.5. 
  At a biochemical level, we reveal that   T  β 4    is a direct target of 
Hand1 and demonstrate the ability of this transcription factor to 
both activate and repress transcription of TB4 by binding at alternate 
E-box sites closely positioned within proximal sequences upstream 
of the functional promoter  11  . Our ChIP data suggest binding of the 
Th   ing1 degenerate E-box in the   T  β 4    proximal regulatory region at 
E8.5 to cause activation of   T  β 4   , and, subsequently at E11.5, a rela-
tively stronger binding of Hand1 to the E-box than to the Th  ing1 
box within the same   T  β 4    upstream element to mediate repression 
of   T  β 4   . It was previously proposed that the inhibitory activity of 
HAND1 may be attributed to multiple mechanisms, such as its 
ability to function as a co-repressor, the presence of a repression 
domain and its ability to sequester E-factors in an inactive com-
plex  26  . In this study, point mutation of the   T  β 4    proximal E-box led 
to increased transcriptional activity, supporting the possibility that 
Hand1 represses, at least in the case of   T  β 4   , by direct DNA binding 
rather than limiting the availability of other bHLH factors through 
sequestration. Interestingly, a point mutation specifi   cally in the 
predicted Hand1-binding half-site of the Th  ing1 box, but not the 
E-factor-binding half, abolished transcriptional activation. Th  is is 
the fi  rst example, of which we are aware, regarding the signifi  cance 
of half-site binding in the context of bHLH heterodimer formation. 
However, in light of our EMSA data (  Fig. 1e  –  g  ), which revealed an 
equivalent reduction in DNA binding for point mutants of either 
the Hand1 or E-Factor half-site within the Th   ing1 box, further stud-
ies are required to determine putative DNA-binding independent 
          Figure  6     |          TB4  rescues  defective  yolk  sac  vasculogenesis  in   Hand1 -null  mutants. Whole-mount immunohistochemistry was performed on Hand1-null 
embryos and heterozygote littermate controls at E8.5 (  a  –  f  ) and E9.5 (  i  –  r  ) using PECAM (  a – f ;   i – n  ) and   α SMA  ( o – r  ) antibodies to visualize the yolk sac 
capillaries and smooth muscle, respectively. A lack of appropriate capillary plexus formation (vasculogenesis) is evident in Hand1-null embryos (  b ,   e ), 
compared with heterozygous littermates at E8.5 (  a ,   d  ). Intraperitoneal (i.p.) injection of pregnant females with TB4 rescued the yolk sac vasculogenic 
defects and an appropriately formed vascular plexus is observed at E8.5 (  c ,   f  ). ELISA revealed a signiﬁ  cant ﬁ  vefold increase in yolk sac TB4 levels 2     h after 
injection  (6   mg   kg     −     1  , i.p.) of pregnant females (  g  ); error bars are s.e.m., where   n     =    mean  protein  concentration  from  six  yolk  sacs  per  treatment.   *  *  *  P     <     0 . 0 0 1  
(Student ’ s   t  -test). TB4 concentration returns to control (uninjected or 2     h PBS) level by 48     h after injection, consistent with a mean terminal half-life of 
1.8  –  2.1     h (human Phase IA study, RegeneRx). qRT  –  PCR revealed that diminished   T  β 4    expression in   Hand1   mutant yolk sacs was elevated to beyond the 
level observed in control   Hand1   heterozygotes after administration of synthetic TB4 (  h  ). Angiogenic remodelling (  i ,   l  ) and smooth muscle recruitment 
(  o ,   q  ) occurred in heterozygous embryos by E9.5 but T  β  4  –  rescued embryos arrested in development before undergoing these processes (  k ,   n ,   p ,   r ). 
Hand1-null embryos are seldom recovered at E9.5. An embryo collected at this stage presented with a primitive, avascular yolk sac and was observed to 
undergo resorption (  j ,   m  ). TB4 injection had no effect on the yolk sac vasculature of wild-type or heterozygous embryos and hence is not shown. Scale 
bars indicate 150       μ m  ( a – c );  100    μ m  ( d – f );  250    μ m  ( i – k );  150    μ m  ( l – n );  250    μ m  ( o – r  ). AU, arbitrary units; ys, yolk sac.   ARTICLE
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mechanisms that might underlie the diff  erential  transcriptional 
regulation by Hand1. 
 Th   ese data, collectively, are consistent with previous results that 
show that HAND1 can function as a negative or positive regula-
tor of transcription  26,27  . Evidence of vascular gene repression by 
Hand1 and the seemingly contradictory lack of vasculogenesis in 
  Hand1  -null embryos, suggest that attempts to compensate for the 
loss of   Hand1   with elevated vascular signalling contributes to the 
impaired vasculogenesis phenotype in mutants. Th  erefore,  Hand1, 
through activation and repression of   T  β 4   , seems to contribute to 
the fi  ne-tuning of the vasculogenic response in the yolk sac in a 
coordinated manner to ensure appropriate temporal and spatial 
regulation of vessel development. Provascular genes are repressed 
at times when vessel formation is not desired and transcriptional 
activation occurs with the onset of vasculogenesis. With specifi  c 
reference to the ChIP data presented, we speculate that, in the case 
of TB4, such Hand1-induced temporal regulation at critical stages, 
between E8.5 and E11.5, may be mediated by a shift   in binding 
from the E-box to the Th   ing1 box. Th   is remains to be fully proven. 
  We herein implicate TB4 in the process of yolk sac vasculogen-
esis, downstream of Hand1. TB4 has recently been recognized for its 
ability to promote coronary vessel development and angiogenesis, 
both in the embryo and in the adult through neovascularization to 
promote cardiac repair  28,29  . Direct parallels can be drawn between 
development of the yolk sac, coronary and gut vasculature, which 
diff  er from the vasculogenesis that occurs in most other tissues. In 
all three cases, vascular precursors arise from a mesoderm-derived 
epithelium, the yolk sac mesothelium  18  , the epicardium  28,30,31   and 
the serosal mesothelium  32  . It may be that the provasculogenic role 
of T  β  4 is restricted to targeting mesothelial tissues specifi  cally for 
the induction of new vessel formation. Notably, both the epicar-
dium and serosal mesothelium retain vasculogenic potential in 
the adult  28,33  , which, in the case of the epicardium, can be induced 
by T  β 4 28  . Given the signifi  cant therapeutic potential of T  β  4 in the 
cardiac setting  6,34   and its current use in clinical trials for conditions 
such as venous stasis and diabetic foot ulcers, epidermolysis bullosa 
and third-degree skin burns (  http://www.regenerx.com/wt/page/
clinical_trials  ), all of which require restoration of the subepidermal 
vascular bed, an understanding of the molecular pathways within 
which T β 4 signals is vital, although it is currently lacking. Upstream 
regulation of   T  β 4    has not previously been demonstrated and the 
identifi  cation of Hand1 in this context is signifi  cant. It remains a 
possibility that Hand1 additionally regulates   T  β 4    expression at later 
embryonic stages, perhaps at time points when T  β  4 is required 
for coronary vasculogenesis. Similarly, very little is known regard-
ing the developmental genes and key signalling pathways that are 
downstream of Hand1  /  T  β  4. We reveal mis-expression of a number 
of provascular genes and their rescue by T  β  4, implicating T  β 4  in 
pathways that directly or indirectly regulate endothelial cell pro-
liferation, migration and diff  erentiation. However, it remains to be 
determined whether Hand1  –  T  β  4 functions to regulate additional 
factors in vascular development and how these molecular cues may 
be used during neovascularization and adult cardiac repair.     
 Methods  
  Plasmids   .     Th  e  T  β  4 luciferase reporter construct consisting of an 870-bp product, 
corresponding to a regulatory region upstream of the   T  β 4    promoter  (    −    2002 
to      −    1132,  relative  to  ATG),  was  PCR-amplifi  ed from mouse cDNA with the intro-
duction of   Kpn I  (5 ′ )  and   Bgl II  (3 ′  ) sites. Th   e cut product was ligated into   Kpn I /
  Bgl  II-digested pGL2-Basic. For deletion constructs, the promoter fragment was 
digested with   Xmn I /  Bgl II  ( Δ   E-box, 770     bp) or   Dra I /  Bgl II  ( Δ   Th   ing1 box, 460     bp) 
and ligated into   Sma I /  Bgl  II-digested pGL2-Basic. Point mutation constructs were 
       Figure  7     |          TB4  restores  appropriate  vasculogenic  gene  and  protein 
expression in the   Hand1  -null yolk sac. Real-time qRT  –  PCR on E8.5 
yolk sacs demonstrated the mis-expression of vascular genes in   Hand1  
homozygous  mutant  yolk  sacs  (    −     /     −    )  compared  with  heterozygous 
yolk  sacs  (    +     /     −    )  and  their  restoration  after  treatment  with  synthetic 
TB4. Elevated levels of   Vegf ,   Flt1   and   Pecam   expression in   Hand1 -null  yolk 
sacs were returned to control levels after TB4 treatment (  a ).  Differential 
expression of   Pecam   was conﬁ  rmed at the protein level by western blotting 
with   α  -PECAM on lysates from E8.5   Hand1  -heterozygous and   Hand1 -
null  yolk  sacs  treated  with  either  vehicle  (    −    TB4)  or  TB4  (    +    TB4):  TB4 
treatment restored elevated PECAM levels in   Hand1   mutants to control 
levels as determined in heterozygous littermates (  b  ). Genes implicated in 
vasculogenic endothelial cell proliferation, migration and differentiation 
(  Tgf  β 1,  Tgf β rII,  Smad5 ,   Endoglin   and   Smad2  ) were also rescued to the control 
levels observed in   Hand1   heterozygous yolk sacs (  c  ). Elevated expression 
of   Notch1 ,   2   and   4   in mutants was also reduced to control levels after 
administration of TB4, to restore appropriate VEGF signalling and vascular 
patterning (  d  ). Error bars are s.e.m., where   n     =    mean  of  three  separate 
qRT  –  PCR experiments on three pooled yolk sacs carried out in triplicate. 
 *  *  P     <     0 . 0 1 ;    *   *   *   P     <    0.001  (Student ’ s   t -test).  ARTICLE   
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created from the full-length reporter construct by site-directed mutagenesis, using 
  QuickChange XL   (  Stratagene  ) and appropriate oligonucleotides to introduce 
the E-box or Th   ing1-box mutations illustrated in   Figure 1  . pcDNA3Hand1 was 
constructed by ligating an   Nde I(fi  lled in)  /    Xho  I fragment of full-length Hand1 into 
pcDNA3 and the tethered heterodimer Hand1  –  ITF2 was constructed by ligating 
a   Bgl I /  Hin  dIII fragment of Hand1 and   Pst I /  Xba  I fragment of ITF2 separated by a 
peptide tether [GT(G  3 -S 7 ) 4 GGGT] 2  35   into  pCMVFlag.   
  Bioinformatics   .    An  ensemble  ( http://www.ensembl.org/index.html )  reference 
sequence, Tmsb4x [NM_021278], chrX: 163643026-163646250, containing the 
murine upstream regulatory region of T  β 4  ( – 2002  to      −    1132,  relative  to  ATG),  was 
entered into the Evolutionary Conserved Regions (ECR) browser at   http://www.
ecrbrowser.dcode.org/ .  Th   e mouse sequence was used as a base against alignments 
with sequenced genomes from six species. Th   e graphical output was a smooth 
conservation plot based on ECRs of 100 nucleotides and 70  %   identity.     
  Mouse strain   .     Th  e    Hand1  -null mouse strain used in this study was generated 
by homologous recombination in embryonic stem cells using a gene targeting 
construct derived from a 129sv genomic library with a 5  ′   arm  (5.7   kb   Bam HI /  Kpn I 
fragment) and 3  ′   arm (2.6     kb   Xho I /  Not I  fragment)  fl  anking a neomyocin resistance 
cassette to replace from 0.3     kb upstream of exon I of the   Hand1   gene to 0.4     kb 
downstream of the translation stop codon in exon 2. Th   e targeting generated a 
functionally null allele in male chimera mice, which was transmitted through 
the germ line  1  . Experiments on animals were carried out under UK Home Offi   ce 
Project Licenses PPL 70  /  6086 and PPL 70  /  6946 in accordance with the UK 
Animals (Scientifi  c Procedures) Act 1986.     
  T    4 rescue in   Hand1 -null  embryos   .    Timed  matings  were  established  between 
  Hand1  -null heterozygous mice. Eighteen pregnant females were injected intraperi-
toneally  with  6   mg   kg     −     1     TB4   (  RegeneRx  ) in 0.1     ml PBS and 12 with vehicle at E4.5 
and E6.5 (E8.5 and E9.5 for collection only). Embryos were collected at E8.5 or 
E9.5 and prepared for immunohistochemistry or qRT  –  PCR analysis.     
  Western blotting      .     Western blotting was performed using standard methods with 
antibodies against   TIE-2 and PECAM   (both from   Santa Cruz  , diluted 1:200), 
 SM α  A   (1:1000) and   Hand1   (1:500, both from   Sigma  ), and     β -tubulin   and   GAPDH  
(both from   Chemicon  , diluted 1:1000). Scanning densitometry was performed and 
signal quantifi  ed using ImageJ.     
  EMSAs      .     EMSAs were carried out essentially as described previously  12 .  Briefl  y, 
  in vitro-  translated Hand1, E12 and tethered Hand1  –  ITF2 heterodimer were incubated 
with   32  P-labelled oligonucleotide in binding buff  er at room temperature for 30     min. 
Unlabelled oligonucleotide (50-fold excess) was used in the competition binding 
assays. Binding reactions were run on a 6  %   tris-borate-EDTA polyacrylamide gel, 
which was dried and subjected to autoradiography.     
  Culture of ﬂ  oating EBs   .    Embryonic  stem  cell  lines  (wild-type      +     /     +    ;  hetero-
zygous      +     /     −    ;  homozygous      −     /     −    )  were  maintained  in  culture,  as  previously 
described.  36   Cells at approximately 80  %   confl  uence were trypsinized and collected 
in leukaemia inhibitory factor-free diff  erentiation medium. Cells (  ~  10  6 )  were 
transferred to 100     mm non-coated bacteriological plates and maintained in fl  oating 
culture for 16 days, with daily feeding. For TB4 rescue experiments, TB4 was added 
to the culture medium at 100     ng     ml      −     1   aft  er the fourth day of diff  erentiation until 
collection. EBs were collected at various time points, washed twice in PBS and snap-
frozen. Poly(A) RNA was isolated using the   Micro-Fast Track 2.0 kit   (  Invitrogen  ) 
and protein extraction was performed using RIPA buff  er and a standard protocol.     
  Reporter transactivation assays      .     NIH-3T3 cells, cultured under standard condi-
tions, were transfected using   Eff  ectene reagent   as described previously  37 .  Briefl  y, 
duplicate wells were transfected with a reporter (the T  β  4 promoter or mutated 
versions thereof, upstream of luciferase in pGL2 basic), along with either 250     ng 
pcDNA3-Hand1 or 250     ng pcDNA3 and a pCMV-  β -galactosidase  ( β -gal)  vector 
to normalize for transfection effi   ciency. Luciferase and   β  -gal activity were assayed 
48   h  aft  er transfection as described  37  ; following normalization, diff  erences in 
RLU /  β  -gal were analysed using a Student  ’  s   t  -test. Each transfection experiment was 
performed three times and a representative data set is shown for each.     
  ChIP      .     Wild-type and Hand1-null EBs were collected aft  er 14 days of diff  erentia-
tion, and washed twice in PBS. E8.5 and E11.5 embryos were dissected in PBS 
containing 0.3  %   Triton X-100. Tissues were immediately cross-linked for 3     h at 
room temperature in ChIP fi  x (1.8  %   formaldehyde, 50     mM HEPES pH7.9, 1     mM 
EDTA, 1     mM EGTA, 100     mM NaCl and 0.09  %   (v  /  v) butyric acid), homogenized 
in lysis buff  er and sonicated. A volume of 60       μ  g of chromatin lysate was used per 
immunoprecipitation with 10       μ g  of   anti-Hand1  antibody   ( Sigma )  in  ChIP  dilution 
buff  er at 4  °  C overnight. A no-antibody procedure was performed in parallel as a 
control. Immune complexes were pulled down with Protein A  /  G beads, washed, 
resuspended in TE (10     mM Tris, 5     mM EDTA, pH 8.0), the cross-links reversed 
overnight at 65  °  C and the DNA purifi  ed. ChIP and no-antibody samples were 
assayed by PCR using primers designed to amplify regions of the T  β 4  proximal 
regulatory region, as illustrated in   Figure 2  .     
  ELISA for T   4       .     Pregnant wild-type female mice were injected with T  β 4  (6   mg   kg     −     1  
in PBS) or vehicle control either 48 or 2     h before collection of E8.5 embryos. 
Protein extracts were prepared from six yolk sacs of each treatment group using 
the RIPA method. A volume of 10       μ  g of total protein was assayed in duplicate using 
a   T  β  4 ELISA kit   (  Immundiagnostik  ), according to manufacturer  ’  s instructions. 
Mean T  β  4 concentration was calculated and signifi  cance determined using a 
Student ’ s   t -test.   
  Whole-mount immunohistochemistry   .    Embryos  were  dissected  in  sterile  PBS, 
within their yolk sacs, and fi  xed in 4  %   (w  /  v) paraformaldehyde for 2     h at room 
temperature. Embryos were treated with 3  %   (v  /  v) hydrogen peroxide in PBS 
to block endogenous peroxidase activity and permeabilized by incubation for 
3 × 15   min  in  PBT  × 0.3   (PBS  containing  0.3 %   Triton  X-100),  2 × 15   min  in  PBT  × 0.5  
(PBS containing 0.5  %   Triton X-100), followed by two further 15     min incubations 
in PBT   × 0.3  . Embryos were blocked for 1     h at room temperature in PBT   × 0.3  / BR  (2 %  
  blocking reagent   (  Roche  ) in PBT   × 0.3 ).  Th   e blocking solution was replaced with 
anti  body, diluted in PBT   × 0.3  / BR  for  overnight  incubation  at  4 ° C  ( biotinylated  rat 
anti-PECAM  ,   BD Pharmingen  , 1:50;   rabbit anti-  α -SMA ,   Abcam ,  1:150).  Following 
two rinses in PBT   × 0.3   and three 1     h washes in PBT   × 0.5  , embryos were blocked for 1     h 
at room temperature in PBT   × 0.3    /  BR and incubated overnight with   biotinylated anti-
rabbit antibody   (  Dako  , 1:100), diluted in BR   × 0.3   (except for PECAM staining, using 
a biotinylated primary antibody when the second day washes and incubation with 
biotinylated secondary antibody were omitted). Aft  er two rinses in PBT   × 0.3   and 
three 1     h washes in PBT   × 0.5  , embryos were incubated with diluted streptavidin  –   
horseradish peroxidase complex (diluted in PBT   × 0.3  / BR),  washed  three  times 
in PBT   × 0.3  , rinsed in PBS and developed using a 3,3  ′ - Diaminobenzidine  Liquid 
Substrate  System   ( Sigma ).  Aft  er imaging, DNA was prepared from embryos for 
genotyping, with primers as shown in   Supplementary Table S1    1 .   
  RNA   in situ   hybridization of embryonic yolk sacs   .    Whole-mount   in situ  
hybridization of embryos retained within the yolk sac was performed, as previously 
described  4   using a T  β 4  3 ′ UTR  riboprobe.   
  qRT  –  PCR of EBs and yolk sac vascular genes   .    For  real-time  qRT – PCR  analysis 
of   Hand1 and   T  β 4    through diff  erentiation, wild-type (R1) and   Hand1 -null  (6.13) 
EBs were collected at days 2, 4, 6, 8, 10, 12, 14 and 16, snap-frozen and total RNA 
extracted using an   RNeasy kit   (  Qiagen  ). For yolk sac vascular genes, embryos were 
collected at E8.5, yolk sacs were snap-frozen and DNA was extracted from embryos. 
Aft  er genotyping, four yolk sacs per genotype  /  treatment group were pooled and 
total RNA was extracted. Linear amplifi  cation of mRNA was performed using a 
 Microarray  Target  Amplifi  cation kit   (  Roche  ), according to manufacturer  ’  s instructions. 
qRT  –  PCR analysis was performed on an   ABI 7000 Sequence Detector   (  Applied 
Biosystems )  using   SYBR  Green   ( Applied  Biosystems ).  Data  were  normalized  to 
  Hprt1   expression and gene expression was calculated using the   Δ  Δ   C t   method 38 . 
  P  -values were obtained using Student  ’  s   t -test  ( n     =    9).  Primers  sequences  were  obtained 
from Primer Bank (  http://www.pga.mgh.harvard.edu/primerbank  ), and are shown 
in   Supplementary Table S1  .     
  Yolk sac immunoﬂ  uorescence      .     Whole-mount embryos with yolk sacs intact were 
dissected and fi  xed as described above. Embryos were removed before yolk sacs 
were blocked and incubated with primary antibody as described above (  Cy3-conju-
gated   α SMA   ( Sigma ,  1:200),   anti-PECAM   ( BD  Pharmingen ,  1:50),   × 3   anti-Hand1  
(  Santa Cruz  , 1:50;   Sigma  , 1:200; and an additional polyclonal anti-Hand1, a kind 
gift   from Dr Orford, 1:200) or   anti-TB4   (  Immundiagnostik  , 1:100)). Aft  er washing, 
as above, the following secondary antibodies were used (all diluted 1:200):   Alexa 
594 -conjugated  anti-rabbit  (T β  4),   Alexa 488-conjugated anti-rabbit   (TB4),   Alexa 
488-conjugated anti-goat   (Hand1) or   Alexa 488-conjugated anti-rat   (PECAM)). 
Nuclei (DNA) were stained with 5     mg     ml      −     1   of bis-benzamide (  Hoechst 33342  ; 
  Sigma  ) in PBS for 10     min at room temperature. Quantitative measures of levels of 
fl  uorescence were determined on images captured at equivalent light intensities 
and fi  lter settings by an investigator blinded to genotype using   ImageJ soft  ware   and 
compared  against  no-primary / secondary  antibody-alone  controls.                      
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